EVIDENCE LIBRARY
Microbiome Study Linked Past Benzodiazepine-Derivative Purchases With Later Microbial Patterns
An observational study found medication-history associations years after use. A persistent microbiome association is not evidence that an active benzodiazepine remained in the body for years.
An observational study found medication-history associations years after use. A persistent microbiome association is not evidence that an active benzodiazepine remained in the body for years.
What was linked
The investigators combined prescription-purchase histories with microbiome data from 2,509 participants. A smaller subgroup had a second microbiome characterization.
Past exposure to several medication classes, including benzodiazepine derivatives, was associated with microbial composition. Changes after starting or stopping treatment were also examined, suggesting questions for causal research.
Persistence has a specific meaning
The measured outcome was a microbiome pattern, not a blood concentration, receptor effect, or impairment test. Long-lasting associations cannot establish drug persistence or ongoing sedation. Illness, repeated treatment, diet, and correlated exposures can contribute.
Purchase was assumed to reflect use, and nonprescription drugs were not fully captured. Volunteer selection, sex imbalance, and relative rather than absolute abundance also limited interpretation. The paper supports including longer medication histories when studying disease–microbiome links, but does not establish clinical injury from a particular benzodiazepine or an exact biological recovery period after discontinuation.
Source paper
Original analysis of the supplied journal article, identified as PMC12542737.